FBXO5 drives hepatocellular carcinoma progression and is a target for tea polyphenol-mediated inhibition

FBXO5 functions as an oncogene in HCC, and TPs may serve as potential therapeutic agents for inhibiting HCC progression by targeting FBXO5.

Authors

Xianglong Wang (ORCID: https://orcid.org/0000-0003-1086-5158)
Xueshan Pan (ORCID: https://orcid.org/0000-0002-9810-3475)
Jun Xia (ORCID: https://orcid.org/0000-0003-3222-2882)
Dandan Yang (ORCID: https://orcid.org/0000-0002-7696-4434)
Jia Ma
Yingjie Zhang (ORCID: https://orcid.org/0000-0002-5936-1025)
Jiao Wang (ORCID: https://orcid.org/0000-0002-1181-4363)
Zheng Huang (ORCID: https://orcid.org/0000-0001-8482-4864)
Junjie Gao (ORCID: https://orcid.org/0000-0001-6869-2013)